Insulin analogues: Impact of cell model characteristics on results and conclusions regarding mitogenic properties

Experimental and Clinical Endocrinology and Diabetes

Volumn 109, Issue 1, 2001, Pages 63-64

  Kellerer, M ^a   Haring H U ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; SOMATOMEDIN C RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; CONCENTRATION RESPONSE; DRUG SAFETY; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN TREATMENT; MITOGENESIS; MOUSE; NONHUMAN; NOTE; OSTEOSARCOMA; PRIORITY JOURNAL; RECEPTOR AFFINITY;

ANIMALS; CELL LINE; HUMANS; INSULIN; MITOGENS; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; TUMOR CELLS, CULTURED;

EID: 0035122343     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-11022     Document Type: Note

References (7)

1. Growth promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32]insulin (HOE 901) in muscle cells
2. The long acting human insulin analog HOE 901: Characteristics of insulin signalling in comparison to Asp(B10) and regular insulin
3. The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake
4. Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency
5. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use
6. Insulin receptor-deficient cells as a new tool for dissecting complex interplay in insulin and insulin-like growth factors